Your browser is not supported.

To view this content, please use one of the following browsers:

  • Microsoft Edge
  • Chrome
  • Safari

Patient Selection & Invokana Benefits

Kidney Heart and Blood Drop

Prescribing Information

Great Britain Northern Ireland

Patient Selection

Which patients can you now prescribe Invokana to?

Invokana can be initiated for patients with type 2 diabetes and is licensed for both cardiovascular and renal protection1-4

  • Patients with insufficiently controlled T2DM who have an eGFR ≥30 mL/min/1.73m2, irrespective of albuminuria status

Abbreviations

eGFR: estimated Glomerular Filtration Rate; SGLT2i: Sodium-Glucose Co-transporter 2 inhibitor; T2DM: Type 2 Diabetes Mellitus; UACR: Urinary Albumin/Creatinine Ratio.

References

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyuk@napp.co.uk.